Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Keith Ahamad

Showing results (21-30 of 38) with videos related to

Pageof 4
Sort By:
The International Journal on Drug Policy|October 31, 2015
Increasing awareness about HIV prevention among young people who initiated injection drug use in a Canadian setting, 1988-2014Anees Bahji, Evan Wood, Keith Ahamad, et al.
The Lancet. HIV|October 2, 2015
Effect of low-threshold methadone maintenance therapy for people who inject drugs on HIV incidence in Vancouver, BC, Canada: an observational cohort studyKeith Ahamad, Kanna Hayashi, Paul Nguyen, et al.
Addiction Science & Clinical Practice|May 4, 2015
Factors associated with willingness to take extended release naltrexone among injection drug usersKeith Ahamad, M J Milloy, Paul Nguyen, et al.
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne|March 7, 2018
Management of opioid use disorders: a national clinical practice guidelineJulie Bruneau, Keith Ahamad, Marie-Ève Goyer, et al.
The American Journal on Addictions|June 12, 2023
Associations of methadone and buprenorphine-naloxone doses with unregulated opioid use, treatment retention, and adverse events in prescription-type opioid use disorders: Exploratory analyses of the OPTIMA studyHamzah Bakouni, Christina McAnulty, Ovidiu Tatar, et al.
Clinical Pharmacology and Therapeutics|November 27, 2023
Pharmacogenetics of Biochemically Verified Abstinence in an Opioid Agonist Therapy Randomized Clinical Trial of Methadone and Buprenorphine/NaloxoneIntishar Kazi, Meghan J Chenoweth, Didier Jutras-Aswad, et al.
Substance Abuse|April 30, 2020
Temporal changes in non-fatal opioid overdose patterns among people who use drugs in a Canadian settingChristopher Fairgrieve, Ekaterina Nosova, M-J Milloy, et al.
The International Journal on Drug Policy|June 6, 2017
Initiating HCV treatment with direct acting agents in opioid agonist treatment: When to start for people co-infected with HIV?Dimitra Panagiotoglou, Emanuel Krebs, Jeong Eun Min, et al.
Journal of Substance Abuse Treatment|January 3, 2018
Increasing diversion of methadone in Vancouver, Canada, 2005-2015Hudson Reddon, Joel Ho, Kora DeBeck, et al.
Addiction (Abingdon, England)|May 6, 2015
Dose-response relationship between methadone dose and adherence to antiretroviral therapy among HIV-positive people who use illicit opioidsLeslie Lappalainen, Seonaid Nolan, Sabina Dobrer, et al.
Pageof 4

Showing results (21-30 of 38) with videos related to

Sort By:
Pageof 4
The International Journal on Drug Policy|October 31, 2015
Increasing awareness about HIV prevention among young people who initiated injection drug use in a Canadian setting, 1988-2014Anees Bahji, Evan Wood, Keith Ahamad, et al.
The Lancet. HIV|October 2, 2015
Effect of low-threshold methadone maintenance therapy for people who inject drugs on HIV incidence in Vancouver, BC, Canada: an observational cohort studyKeith Ahamad, Kanna Hayashi, Paul Nguyen, et al.
Addiction Science & Clinical Practice|May 4, 2015
Factors associated with willingness to take extended release naltrexone among injection drug usersKeith Ahamad, M J Milloy, Paul Nguyen, et al.
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne|March 7, 2018
Management of opioid use disorders: a national clinical practice guidelineJulie Bruneau, Keith Ahamad, Marie-Ève Goyer, et al.
The American Journal on Addictions|June 12, 2023
Associations of methadone and buprenorphine-naloxone doses with unregulated opioid use, treatment retention, and adverse events in prescription-type opioid use disorders: Exploratory analyses of the OPTIMA studyHamzah Bakouni, Christina McAnulty, Ovidiu Tatar, et al.
Clinical Pharmacology and Therapeutics|November 27, 2023
Pharmacogenetics of Biochemically Verified Abstinence in an Opioid Agonist Therapy Randomized Clinical Trial of Methadone and Buprenorphine/NaloxoneIntishar Kazi, Meghan J Chenoweth, Didier Jutras-Aswad, et al.
Substance Abuse|April 30, 2020
Temporal changes in non-fatal opioid overdose patterns among people who use drugs in a Canadian settingChristopher Fairgrieve, Ekaterina Nosova, M-J Milloy, et al.
The International Journal on Drug Policy|June 6, 2017
Initiating HCV treatment with direct acting agents in opioid agonist treatment: When to start for people co-infected with HIV?Dimitra Panagiotoglou, Emanuel Krebs, Jeong Eun Min, et al.
Journal of Substance Abuse Treatment|January 3, 2018
Increasing diversion of methadone in Vancouver, Canada, 2005-2015Hudson Reddon, Joel Ho, Kora DeBeck, et al.
Addiction (Abingdon, England)|May 6, 2015
Dose-response relationship between methadone dose and adherence to antiretroviral therapy among HIV-positive people who use illicit opioidsLeslie Lappalainen, Seonaid Nolan, Sabina Dobrer, et al.
Pageof 4